Birchler Brian 4

What Happened Brian Birchler, Executive Vice President, Corporate and Development Operations at Ionis Pharmaceuticals (IONS), had 11,991 performance-based restricted stock units (PRSUs) vest on 2026-01-29 (awarded at $0 cost). On 2026-01-30 he sold 6,179 of those shares in open-market transactions for a weighted average price of $83.03, generating approximately $513,048 in proceeds. The award reflects a certified payout level of 167.27% of target for the PRSU performance period.

Key Details

• Transactions: 11,991 shares awarded (vested) on 2026-01-29; 6,179 shares sold on 2026-01-30.
• Prices/values: Award reported at $0 (vested RSUs). Sale weighted average price $83.03; sale proceeds ≈ $513,048. Sales ranged $83.00–$83.08 (footnote).
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1 — PRSU vesting based on relative total shareholder return vs. peer group; payout = 167.27% of target (range 0–200%). F2 — sale price is a weighted average across multiple transactions; reporting person will provide per-price detail on request.
• Filing timeliness: Reported on 2026-02-02 for transactions on 2026-01-29 and 2026-01-30; this appears to be within the typical two-business-day Form 4 filing window.

Context The 11,991 shares were earned via vesting of performance-based RSUs granted earlier (grant reported 2023-01-18); such awards are reported as acquisitions at $0 because they were issued, not purchased. The subsequent open-market sale of 6,179 shares is a disposition reported separately. The filing does not state a reason for the sale; filings typically do not indicate insider motives.